Amooranin, a Plant Compound, Shows Potential as Cancer Treatment

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 1
Volume 15
Issue 1

Amooranin (AMR), derived from the Amoora rohituka stem bark, shows clinical potential in treating human cancers, Steven Melnick, MD, PhD, said at the Society for Integrative Oncology (SIO) annual meeting (abstract 57). Dr. Melnick, chief, Department of Pathology and Clinical Laboratories, Miami Children's Hospital, said that the Amoora rohituka stem bark is one of the components of a natural preparation used for the treatment of human malignancies in the Ayurvedic system of medicine in India. Derived from stem bark that grows wild in Asia, the preparation contains parts of three medicinal plants: Amoora rohituka stem bark, Glycyrrhiza glabra roots, and Semicarpus anacardium fruits.

SAN DIEGO—Amooranin (AMR), derived from the Amoora rohituka stem bark, shows clinical potential in treating human cancers, Steven Melnick, MD, PhD, said at the Society for Integrative Oncology (SIO) annual meeting (abstract 57). Dr. Melnick, chief, Department of Pathology and Clinical Laboratories, Miami Children's Hospital, said that the Amoora rohituka stem bark is one of the components of a natural preparation used for the treatment of human malignancies in the Ayurvedic system of medicine in India. Derived from stem bark that grows wild in Asia, the preparation contains parts of three medicinal plants: Amoora rohituka stem bark, Glycyrrhiza glabra roots, and Semicarpus anacardium fruits.

Cytotoxicity

Amooranin is a triterpenic acid with an oleanolic acid skeleton; it is cytotoxic to an array of tumor cell lines from different organs, with cytotoxicity values ranging from 2.5 to 6.9 ?g/mL. "We identified cytotoxicity in a variety of cancer cell lines, evidence of G2/M cell arrest, reversal of drug resistance, apoptosis, and inhibition of COX-2 mRNA expression," Dr. Melnick said. At lower concentrations, he said, amooranin reversed multidrug resistance by blocking P-glycoprotein-mediated doxorubicin efflux, and could be used in combination since it potentiates other cancer drugs. He noted that amooranin and doxorubicin in relatively low concentrations created a synergy that reduced resistance in human tumor xenografts in nude mice.

The amooranin treatment showed significant reduction in tumor growth rate, compared to saline and doxorubicin control treatments, with the lowest dose of 2 mg/kg producing higher inhibition rates than larger doses. "We found that more is not necessarily better," Dr. Melnick said. "Looking at survival, both amooranin and doxorubicin at 2 mg/kg were equally efficacious."

Upregulates Certain Genes

Microarray analyses and gene-expressive protocols performed on the tumors showed that 147 genes were upregulated at least threefold and 57 genes were down-regulated at least threefold at all doses of amooranin. "Amooranin specifically upregulated several genes involved in drug transport, cell signaling, cytochrome C release, apoptosis, G2/M cell arrest, and inflammatory response," he said. "And we found that it downregulates genes involved in angiogenesis and inflammatory response." The results show that amooranin has good clinical potential for treating human malignancies, Dr. Melnick concluded. These, he said, will be explored in early clinical trials.

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content